Pardes Biosciences, Inc. (PRDS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Carlsbad, CA, United States. El CEO actual es Thomas G. Wiggans.
PRDS tiene fecha de IPO 2021-12-27, 57 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $135.19M.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
